Table 3.
The effect of Omega-3 and lead acetate on specific activity of liver and kidney antioxidant enzymes in female rats.
| Parameters | Experimental groups | |||
|---|---|---|---|---|
| (Group 1) −ve control |
(Group 2) Omega-3 (125 mg/kg b.w.) + lead acetate |
(Group 3) Omega-3 (260 mg/kg b.w.) + lead acetate |
(Group 4) +ve control |
|
| Liver | ||||
| GPX (U/mg protein) | 40.53 ± 0.240a | 36.54 ± 0.909a | 48.50 ± 0.341a | 22.44 ± 0.487b |
| CAT (U/mg protein) | 27.53 ± 0.554a | 23.92 ± 0.583a | 34.46 ± 0.743a | 16.67 ± 0.489b |
| SOD (U/mg protein) | 11.34 ± 0.355a | 10.40 ± 0.346a | 18.11 ± 0.495b | 7.64 ± 0.303c |
| GSH (U/g tissue) | 27.84 ± 0.312a | 26.08 ± 0.446a | 29.16 ± 0.271a | 12.72 ± 0.303b |
| MDA (nmol/g tissue) | 50.34 ± 0.259a | 54.62 ± 0.288a | 51.41 ± 0.282a | 100.54 ± 0.322b |
| Kidney | ||||
| GPX (U/mg protein) | 30.64 ± 0.521a | 27.43 ± 0.597a | 39.89 ± 0.479b | 21.54 ± 0.360c |
| CAT (U/mg protein) | 53.17 ± 0.477a | 46.97 ± 0.557a | 63.30 ± 0.583b | 20.41 ± 0.562c |
| SOD (U/mg protein) | 98.92 ± 0.457a | 81.99 ± 0.693a | 98.60 ± 0.285a | 41.75 ± 0.451b |
| GSH (U/g tissue) | 53.81 ± 0.682a | 50.39 ± 0.350a | 55.01 ± 0.724a | 28.51 ± 0.334b |
| MDA (nmol/g tissue) | 22.19 ± 0.320a | 37.60 ± 0.382b | 22.94 ± 0.515a | 51.82 ± 0.313c |
Values are expressed as means ± SE; n = 7 for each treatment group. a, b, and c indicate the significant results statistically; P < 0.05.